Eli Lilly and Company (LLY)

550.54 +0.41 (+0.07%) At close: 04:01PM EDT

Eli Lilly and Company

Lilly Corporate Center
Indianapolis, IN 46285
United States
317 276 2000
https://www.lilly.com

Sector(s): Healthcare
Industry: Drug Manufacturers—General
Full Time Employees: 39,000

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. David A. Ricks	Chairman, CEO & Pres	4.42M	N/A	1968
Ms. Anat Ashkenazi	Exec. VP & CFO	2.13M	N/A	1973
Dr. Daniel M. Skovronsky M.D., Ph.D.	Exec. VP, Chief Scientific & Medical Officer and Pres of Lilly Research Laboratories	2.72M	N/A	1974
Ms. Anat Hakim J.D.	Exec. VP, Gen. Counsel & Sec.	1.98M	N/A	1969
Mr. Patrik Jonsson	EVP, Chief Customer Officer, Pres of Lilly USA & Lilly Immunology	1.67M	N/A	1967
Mr. Donald A. Zakrowski	Chief Accounting Officer & VP of Fin.	N/A	N/A	N/A
Mr. Diogo Rau	EVP & Chief Information and Digital Officer	N/A	N/A	N/A
Mr. Alonzo Weems	EVP of Enterprise Risk Management and Chief Ethics & Compliance Officer	N/A	N/A	1971
Ms. Leigh Ann Pusey	Exec. VP of Corp. Affairs & Communications	N/A	N/A	1963
Mr. Eric Dozier	Exec. VP of HR & Diversity	N/A	N/A	1967

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Corporate Governance

Eli Lilly and Company’s ISS Governance QualityScore as of September 1, 2023 is 5. The pillar scores are Audit: 3; Board: 5; Shareholder Rights: 9; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.